

# Global Duchenne Muscular Dystrophy Drugs Market Research Report 2022 Professional Edition

<https://marketpublishers.com/r/GF49F223108BEN.html>

Date: January 2022

Pages: 144

Price: US\$ 2,890.00 (Single User License)

ID: GF49F223108BEN

## Abstracts

The global Duchenne Muscular Dystrophy Drugs market was valued at 1210.45 Million USD in 2021 and will grow with a CAGR of 29.35% from 2021 to 2027, based on HNY Research newly published report.

The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market vendors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).

Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essential for maintaining healthy muscle function) in individuals. The lack of dystrophin weakens muscle function, causes loss of ambulation, harms the respiratory and cardiac function, and ultimately leads to death. The main symptoms of this condition appears in childhood and includes delay of motor functions; progressive muscle weakness; muscle contractures in legs; and muscle weakness in arms, neck, and more severely in the lower half of the body. The bones also develop peculiarly, causing skeletal deformities in the patient. Occurrences of pseudo-hypertrophy, cardiomyopathy, and breathing complications are some of the other symptoms of this condition.

By Market Vendors:

Akashi Therapeutics Inc

Antisense Therapeutics Ltd

Beech Tree Labs Inc

Biogen Inc

Bioleaders Corp

BioMarin Pharmaceutical Inc

Biophytis SAS

Capricor Therapeutics Inc

Catabasis Pharmaceuticals Inc

CRISPR Therapeutics

Cumberland Pharmaceuticals Inc

Daiichi Sankyo Co Ltd

Debiopharm International SA

Editas Medicine Inc

Eloxx Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

FibroGen Inc

Fulcrum Therapeutics Inc

Galapagos NV

Genethon SA

GTx Inc

Santhera Pharmaceuticals Holding AG

Sarepta Therapeutics Inc

SOM Biotech SL

Strykagen Corp

Summit Therapeutics Plc

Taiho Pharmaceutical Co Ltd

Teijin Pharma Ltd

WAVE Life Sciences Ltd

By Types:

Development & Drug Target

Mechanism of Action (MoA)

Route of Administration (RoA)

Molecule Type

By Applications:

Hospitals and Clinics

Medical Laboratories

Key Indicators Analysed

**Market Players & Competitor Analysis:** The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the

market's competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.

**Global and Regional Market Analysis:** The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.

**Market Trends:** Market key trends which include Increased Competition and Continuous Innovations.

**Opportunities and Drivers:** Identifying the Growing Demands and New Technology

**Porters Five Force Analysis:** The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

**Key Reasons to Purchase**

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.

Assess the production processes, major issues, and solutions to mitigate the development risk.

To understand the most affecting driving and restraining forces in the market and its impact in the global market.

Learn about the market strategies that are being adopted by leading respective organizations.

To understand the future outlook and prospects for the market.

Besides the standard structure reports, we also provide custom research according to specific requirements

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue

1.4 Market Analysis by Type

1.4.1 Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate by Type:  
2021 VS 2027

1.4.2 Development & Drug Target

1.4.3 Mechanism of Action (MoA)

1.4.4 Route of Administration (RoA)

1.4.5 Molecule Type

1.5 Market by Application

1.5.1 Global Duchenne Muscular Dystrophy Drugs Market Share by Application:  
2022-2027

1.5.2 Hospitals and Clinics

1.5.3 Medical Laboratories

1.6 Study Objectives

1.7 Years Considered

1.8 Overview of Global Duchenne Muscular Dystrophy Drugs Market

1.8.1 Global Duchenne Muscular Dystrophy Drugs Market Status and Outlook  
(2016-2027)

1.8.2 North America

1.8.3 East Asia

1.8.4 Europe

1.8.5 South Asia

1.8.6 Southeast Asia

1.8.7 Middle East

1.8.8 Africa

1.8.9 Oceania

1.8.10 South America

1.8.11 Rest of the World

### 2 MARKET COMPETITION BY MANUFACTURERS

2.1 Global Duchenne Muscular Dystrophy Drugs Production Capacity Market Share by  
Manufacturers (2016-2021)

- 2.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Manufacturers (2016-2021)
- 2.3 Global Duchenne Muscular Dystrophy Drugs Average Price by Manufacturers (2016-2021)
- 2.4 Manufacturers Duchenne Muscular Dystrophy Drugs Production Sites, Area Served, Product Type

### **3 SALES BY REGION**

- 3.1 Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Region (2016-2021)
- 3.2 Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share by Region (2016-2021)
- 3.3 North America Duchenne Muscular Dystrophy Drugs Sales Volume
  - 3.3.1 North America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)
  - 3.3.2 North America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
- 3.4 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume
  - 3.4.1 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)
  - 3.4.2 East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
- 3.5 Europe Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)
  - 3.5.1 Europe Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)
  - 3.5.2 Europe Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
- 3.6 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)
  - 3.6.1 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)
  - 3.6.2 South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
- 3.7 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)
  - 3.7.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)
  - 3.7.2 Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
- 3.8 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)

3.8.1 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

3.8.2 Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.9 Africa Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)

3.9.1 Africa Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

3.9.2 Africa Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.10 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)

3.10.1 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

3.10.2 Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.11 South America Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)

3.11.1 South America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

3.11.2 South America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

3.12 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume (2016-2021)

3.12.1 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

3.12.2 Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

## **4 NORTH AMERICA**

4.1 North America Duchenne Muscular Dystrophy Drugs Consumption by Countries

4.2 United States

4.3 Canada

4.4 Mexico

## **5 EAST ASIA**

5.1 East Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries

5.2 China

5.3 Japan

5.4 South Korea

## **6 EUROPE**

6.1 Europe Duchenne Muscular Dystrophy Drugs Consumption by Countries

6.2 Germany

6.3 United Kingdom

6.4 France

6.5 Italy

6.6 Russia

6.7 Spain

6.8 Netherlands

6.9 Switzerland

6.10 Poland

## **7 SOUTH ASIA**

7.1 South Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries

7.2 India

7.3 Pakistan

7.4 Bangladesh

## **8 SOUTHEAST ASIA**

8.1 Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries

8.2 Indonesia

8.3 Thailand

8.4 Singapore

8.5 Malaysia

8.6 Philippines

8.7 Vietnam

8.8 Myanmar

## **9 MIDDLE EAST**

9.1 Middle East Duchenne Muscular Dystrophy Drugs Consumption by Countries

9.2 Turkey

9.3 Saudi Arabia

9.4 Iran

9.5 United Arab Emirates



- 9.6 Israel
- 9.7 Iraq
- 9.8 Qatar
- 9.9 Kuwait
- 9.10 Oman

## **10 AFRICA**

- 10.1 Africa Duchenne Muscular Dystrophy Drugs Consumption by Countries
- 10.2 Nigeria
- 10.3 South Africa
- 10.4 Egypt
- 10.5 Algeria
- 10.6 Morocco

## **11 OCEANIA**

- 11.1 Oceania Duchenne Muscular Dystrophy Drugs Consumption by Countries
- 11.2 Australia
- 11.3 New Zealand

## **12 SOUTH AMERICA**

- 12.1 South America Duchenne Muscular Dystrophy Drugs Consumption by Countries
- 12.2 Brazil
- 12.3 Argentina
- 12.4 Columbia
- 12.5 Chile
- 12.6 Venezuela
- 12.7 Peru
- 12.8 Puerto Rico
- 12.9 Ecuador

## **13 REST OF THE WORLD**

- 13.1 Rest of the World Duchenne Muscular Dystrophy Drugs Consumption by Countries
- 13.2 Kazakhstan

## **14 SALES VOLUME, SALES REVENUE, SALES PRICE TREND BY TYPE**

14.1 Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Type (2016-2021)

14.2 Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share by Type (2016-2021)

14.3 Global Duchenne Muscular Dystrophy Drugs Sales Price by Type (2016-2021)

## **15 CONSUMPTION ANALYSIS BY APPLICATION**

15.1 Global Duchenne Muscular Dystrophy Drugs Consumption Volume by Application (2016-2021)

15.2 Global Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2016-2021)

## **16 COMPANY PROFILES AND KEY FIGURES IN DUCHENNE MUSCULAR DYSTROPHY DRUGS BUSINESS**

16.1 Akashi Therapeutics Inc

16.1.1 Akashi Therapeutics Inc Company Profile

16.1.2 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.1.3 Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.2 Antisense Therapeutics Ltd

16.2.1 Antisense Therapeutics Ltd Company Profile

16.2.2 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.2.3 Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.3 Beech Tree Labs Inc

16.3.1 Beech Tree Labs Inc Company Profile

16.3.2 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.3.3 Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.4 Biogen Inc

16.4.1 Biogen Inc Company Profile

16.4.2 Biogen Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.4.3 Biogen Inc Duchenne Muscular Dystrophy Drugs Production Capacity,

## Revenue, Price and Gross Margin (2016-2021)

### 16.5 Bioleaders Corp

#### 16.5.1 Bioleaders Corp Company Profile

#### 16.5.2 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.5.3 Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.6 BioMarin Pharmaceutical Inc

#### 16.6.1 BioMarin Pharmaceutical Inc Company Profile

#### 16.6.2 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.6.3 BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.7 Biophytis SAS

#### 16.7.1 Biophytis SAS Company Profile

#### 16.7.2 Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.7.3 Biophytis SAS Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.8 Capricor Therapeutics Inc

#### 16.8.1 Capricor Therapeutics Inc Company Profile

#### 16.8.2 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.8.3 Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.9 Catabasis Pharmaceuticals Inc

#### 16.9.1 Catabasis Pharmaceuticals Inc Company Profile

#### 16.9.2 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.9.3 Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.10 CRISPR Therapeutics

#### 16.10.1 CRISPR Therapeutics Company Profile

#### 16.10.2 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Specification

#### 16.10.3 CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

### 16.11 Cumberland Pharmaceuticals Inc

#### 16.11.1 Cumberland Pharmaceuticals Inc Company Profile

#### 16.11.2 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.11.3 Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.12 Daiichi Sankyo Co Ltd

16.12.1 Daiichi Sankyo Co Ltd Company Profile

16.12.2 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.12.3 Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.13 Debiopharm International SA

16.13.1 Debiopharm International SA Company Profile

16.13.2 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Specification

16.13.3 Debiopharm International SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.14 Editas Medicine Inc

16.14.1 Editas Medicine Inc Company Profile

16.14.2 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.14.3 Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.15 Eloxx Pharmaceuticals Inc

16.15.1 Eloxx Pharmaceuticals Inc Company Profile

16.15.2 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.15.3 Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.16 F. Hoffmann-La Roche Ltd

16.16.1 F. Hoffmann-La Roche Ltd Company Profile

16.16.2 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.16.3 F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.17 FibroGen Inc

16.17.1 FibroGen Inc Company Profile

16.17.2 FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.17.3 FibroGen Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.18 Fulcrum Therapeutics Inc

16.18.1 Fulcrum Therapeutics Inc Company Profile

16.18.2 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.18.3 Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.19 Galapagos NV

16.19.1 Galapagos NV Company Profile

16.19.2 Galapagos NV Duchenne Muscular Dystrophy Drugs Product Specification

16.19.3 Galapagos NV Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.20 Genethon SA

16.20.1 Genethon SA Company Profile

16.20.2 Genethon SA Duchenne Muscular Dystrophy Drugs Product Specification

16.20.3 Genethon SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.21 GTx Inc

16.21.1 GTx Inc Company Profile

16.21.2 GTx Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.21.3 GTx Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.22 Santhera Pharmaceuticals Holding AG

16.22.1 Santhera Pharmaceuticals Holding AG Company Profile

16.22.2 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Specification

16.22.3 Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.23 Sarepta Therapeutics Inc

16.23.1 Sarepta Therapeutics Inc Company Profile

16.23.2 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

16.23.3 Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.24 SOM Biotech SL

16.24.1 SOM Biotech SL Company Profile

16.24.2 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Specification

16.24.3 SOM Biotech SL Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.25 Strykagen Corp

16.25.1 Strykagen Corp Company Profile

16.25.2 Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Specification

16.25.3 Strykagen Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.26 Summit Therapeutics Plc

16.26.1 Summit Therapeutics Plc Company Profile

16.26.2 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Specification

16.26.3 Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.27 Taiho Pharmaceutical Co Ltd

16.27.1 Taiho Pharmaceutical Co Ltd Company Profile

16.27.2 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.27.3 Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.28 Teijin Pharma Ltd

16.28.1 Teijin Pharma Ltd Company Profile

16.28.2 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.28.3 Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

16.29 WAVE Life Sciences Ltd

16.29.1 WAVE Life Sciences Ltd Company Profile

16.29.2 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Specification

16.29.3 WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

## **17 DUCHENNE MUSCULAR DYSTROPHY DRUGS MANUFACTURING COST ANALYSIS**

17.1 Duchenne Muscular Dystrophy Drugs Key Raw Materials Analysis

17.1.1 Key Raw Materials

17.2 Proportion of Manufacturing Cost Structure

17.3 Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs

17.4 Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis

## **18 MARKETING CHANNEL, DISTRIBUTORS AND CUSTOMERS**

18.1 Marketing Channel

18.2 Duchenne Muscular Dystrophy Drugs Distributors List



### 18.3 Duchenne Muscular Dystrophy Drugs Customers

## 19 MARKET DYNAMICS

### 19.1 Market Trends

### 19.2 Opportunities and Drivers

### 19.3 Challenges

### 19.4 Porter's Five Forces Analysis

## 20 PRODUCTION AND SUPPLY FORECAST

### 20.1 Global Forecasted Production of Duchenne Muscular Dystrophy Drugs (2022-2027)

### 20.2 Global Forecasted Revenue of Duchenne Muscular Dystrophy Drugs (2022-2027)

### 20.3 Global Forecasted Price of Duchenne Muscular Dystrophy Drugs (2016-2027)

### 20.4 Global Forecasted Production of Duchenne Muscular Dystrophy Drugs by Region (2022-2027)

#### 20.4.1 North America Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.2 East Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.3 Europe Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.4 South Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.5 Southeast Asia Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.6 Middle East Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.7 Africa Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.8 Oceania Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.9 South America Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

#### 20.4.10 Rest of the World Duchenne Muscular Dystrophy Drugs Production, Revenue Forecast (2022-2027)

### 20.5 Forecast by Type and by Application (2022-2027)

#### 20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type

(2022-2027)

20.5.2 Global Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Application (2022-2027)

## **21 CONSUMPTION AND DEMAND FORECAST**

21.1 North America Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.2 East Asia Market Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.3 Europe Market Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.4 South Asia Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.5 Southeast Asia Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.6 Middle East Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.7 Africa Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.8 Oceania Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.9 South America Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

21.10 Rest of the world Forecasted Consumption of Duchenne Muscular Dystrophy Drugs by Country

## **22 RESEARCH FINDINGS AND CONCLUSION**

## **23 METHODOLOGY AND DATA SOURCE**

23.1 Methodology/Research Approach

23.1.1 Research Programs/Design

23.1.2 Market Size Estimation

23.1.3 Market Breakdown and Data Triangulation

23.2 Data Source

23.2.1 Secondary Sources

23.2.2 Primary Sources

23.3 Disclaimer





## List Of Tables

### LIST OF TABLES AND FIGURES

Key Players Covered: Ranking by Duchenne Muscular Dystrophy Drugs Revenue (US\$ Million) 2016-2021

Global Duchenne Muscular Dystrophy Drugs Market Size by Type (US\$ Million):  
2022-2027

Global Duchenne Muscular Dystrophy Drugs Market Size by Application (US\$ Million):  
2022-2027

Global Duchenne Muscular Dystrophy Drugs Production Capacity by Manufacturers

Global Duchenne Muscular Dystrophy Drugs Production by Manufacturers (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Production Market Share by  
Manufacturers (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Revenue by Manufacturers (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Revenue Share by Manufacturers  
(2016-2021)

Global Market Duchenne Muscular Dystrophy Drugs Average Price of Key  
Manufacturers (2016-2021)

Manufacturers Duchenne Muscular Dystrophy Drugs Production Sites and Area Served

Manufacturers Duchenne Muscular Dystrophy Drugs Product Type

Global Duchenne Muscular Dystrophy Drugs Sales Volume by Region (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Region  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue by Region (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share by Region

(2016-2021)

North America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Europe Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Africa Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

South America Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)

North America Duchenne Muscular Dystrophy Drugs Consumption by Countries (2016-2021)

East Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries (2016-2021)

Europe Duchenne Muscular Dystrophy Drugs Consumption by Region (2016-2021)

South Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries  
(2016-2021)

Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption by Countries  
(2016-2021)

Middle East Duchenne Muscular Dystrophy Drugs Consumption by Countries  
(2016-2021)

Africa Duchenne Muscular Dystrophy Drugs Consumption by Countries (2016-2021)

Oceania Duchenne Muscular Dystrophy Drugs Consumption by Countries (2016-2021)

South America Duchenne Muscular Dystrophy Drugs Consumption by Countries  
(2016-2021)

Rest of the World Duchenne Muscular Dystrophy Drugs Consumption by Countries  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Volume by Type (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share by Type  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue by Type (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue Share by Type  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Sales Price by Type (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Consumption Volume by Application  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Consumption Volume Market Share by  
Application (2016-2021)

Global Duchenne Muscular Dystrophy Drugs Consumption Value by Application  
(2016-2021)

Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Application (2016-2021)

Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Table Biogen Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Bioleaders Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Biophytis SAS Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Debiopharm International SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

FibroGen Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Galapagos NV Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Genethon SA Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

GTx Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

SOM Biotech SL Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Strykagen Corp Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)

Duchenne Muscular Dystrophy Drugs Distributors List

Duchenne Muscular Dystrophy Drugs Customers List

Market Key Trends

Key Opportunities and Drivers: Impact Analysis (2022-2027)

Key Challenges

Global Duchenne Muscular Dystrophy Drugs Production Forecast by Region (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Sales Volume Forecast by Type (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Sales Volume Market Share Forecast by Type (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue Forecast by Type (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Sales Revenue Market Share Forecast by Type (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Sales Price Forecast by Type (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Consumption Volume Forecast by Application (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Consumption Value Forecast by Application (2022-2027)

North America Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

East Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

South Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Middle East Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Africa Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Oceania Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

South America Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Rest of the world Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027 by Country

Research Programs/Design for This Report



Key Data Information from Secondary Sources

Key Data Information from Primary Sources

Global Duchenne Muscular Dystrophy Drugs Market Share by Type: 2021 VS 2027

Development & Drug Target Features

Mechanism of Action (MoA) Features

Route of Administration (RoA) Features

Molecule Type Features

Global Duchenne Muscular Dystrophy Drugs Market Share by Application: 2021 VS 2027

Hospitals and Clinics Case Studies

Medical Laboratories Case Studies

Duchenne Muscular Dystrophy Drugs Report Years Considered

Global Duchenne Muscular Dystrophy Drugs Market Status and Outlook (2016-2027)

North America Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

East Asia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

Europe Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

South Asia Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate

(2016-2027)

South America Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

Middle East Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

Africa Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

Oceania Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

South America Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

Rest of the World Duchenne Muscular Dystrophy Drugs Revenue (Value) and Growth Rate (2016-2027)

North America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

East Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Europe Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

South Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Southeast Asia Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Middle East Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Africa Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Oceania Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

South America Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

Rest of the World Duchenne Muscular Dystrophy Drugs Sales Volume Growth Rate (2016-2021)

North America Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

North America Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

United States Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Canada Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Mexico Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

East Asia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

East Asia Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

China Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Japan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

South Korea Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Europe Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Europe Duchenne Muscular Dystrophy Drugs Consumption Market Share by Region in 2021

Germany Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

United Kingdom Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

France Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Italy Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Russia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Spain Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Netherlands Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Switzerland Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Poland Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

South Asia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

South Asia Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

India Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Pakistan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Bangladesh Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption Market Share by  
Countries in 2021

Indonesia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Thailand Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Singapore Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Malaysia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Philippines Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Vietnam Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Myanmar Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Middle East Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Middle East Duchenne Muscular Dystrophy Drugs Consumption Market Share by  
Countries in 2021

Turkey Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate  
(2016-2021)

Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

(2016-2021)

Iran Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

United Arab Emirates Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Israel Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Iraq Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Qatar Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Kuwait Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Oman Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Africa Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Africa Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

Nigeria Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

South Africa Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Egypt Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Algeria Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Morocco Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

(2016-2021)

Oceania Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Oceania Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

Australia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

New Zealand Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

South America Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

South America Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

Brazil Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Argentina Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Columbia Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Chile Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Venezuela Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Peru Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Puerto Rico Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Ecuador Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Rest of the World Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate

Rest of the World Duchenne Muscular Dystrophy Drugs Consumption Market Share by Countries in 2021

Kazakhstan Duchenne Muscular Dystrophy Drugs Consumption and Growth Rate (2016-2021)

Sales Market Share of Duchenne Muscular Dystrophy Drugs by Type in 2021

Sales Revenue Market Share of Duchenne Muscular Dystrophy Drugs by Type in 2021

Global Duchenne Muscular Dystrophy Drugs Consumption Volume Market Share by Application in 2021

Akashi Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

Antisense Therapeutics Ltd Duchenne Muscular Dystrophy Drugs Product Specification

Beech Tree Labs Inc Duchenne Muscular Dystrophy Drugs Product Specification

Biogen Inc Duchenne Muscular Dystrophy Drugs Product Specification

Bioleaders Corp Duchenne Muscular Dystrophy Drugs Product Specification

BioMarin Pharmaceutical Inc Duchenne Muscular Dystrophy Drugs Product Specification

Biophytis SAS Duchenne Muscular Dystrophy Drugs Product Specification

Capricor Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

Catabasis Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification

CRISPR Therapeutics Duchenne Muscular Dystrophy Drugs Product Specification

Cumberland Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product



## Specification

Daiichi Sankyo Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification

Debiopharm International SA Duchenne Muscular Dystrophy Drugs Product Specification

Editas Medicine Inc Duchenne Muscular Dystrophy Drugs Product Specification

Eloxx Pharmaceuticals Inc Duchenne Muscular Dystrophy Drugs Product Specification

F. Hoffmann-La Roche Ltd Duchenne Muscular Dystrophy Drugs Product Specification

FibroGen Inc Duchenne Muscular Dystrophy Drugs Product Specification

Fulcrum Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

Galapagos NV Duchenne Muscular Dystrophy Drugs Product Specification

Genethon SA Duchenne Muscular Dystrophy Drugs Product Specification

GTx Inc Duchenne Muscular Dystrophy Drugs Product Specification

Santhera Pharmaceuticals Holding AG Duchenne Muscular Dystrophy Drugs Product Specification

Sarepta Therapeutics Inc Duchenne Muscular Dystrophy Drugs Product Specification

SOM Biotech SL Duchenne Muscular Dystrophy Drugs Product Specification

Strykagen Corp Duchenne Muscular Dystrophy Drugs Product Specification

Summit Therapeutics Plc Duchenne Muscular Dystrophy Drugs Product Specification

Taiho Pharmaceutical Co Ltd Duchenne Muscular Dystrophy Drugs Product Specification

Teijin Pharma Ltd Duchenne Muscular Dystrophy Drugs Product Specification

WAVE Life Sciences Ltd Duchenne Muscular Dystrophy Drugs Product Specification

Manufacturing Cost Structure of Duchenne Muscular Dystrophy Drugs

Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs

Duchenne Muscular Dystrophy Drugs Industrial Chain Analysis

Channels of Distribution

Distributors Profiles

Porter's Five Forces Analysis

Global Duchenne Muscular Dystrophy Drugs Production Capacity Growth Rate Forecast (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast (2022-2027)

Global Duchenne Muscular Dystrophy Drugs Price and Trend Forecast (2016-2027)

North America Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast (2022-2027)

North America Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast (2022-2027)

East Asia Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast (2022-2027)

East Asia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast (2022-2027)

Europe Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast (2022-2027)

Europe Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast (2022-2027)

South Asia Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

South Asia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

Southeast Asia Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

Southeast Asia Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

Middle East Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

Middle East Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

Africa Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

Africa Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

Oceania Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

Oceania Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

South America Duchenne Muscular Dystrophy Drugs Production Growth Rate Forecast  
(2022-2027)

South America Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast  
(2022-2027)

Rest of the World Duchenne Muscular Dystrophy Drugs Production Growth Rate  
Forecast (2022-2027)

Rest of the World Duchenne Muscular Dystrophy Drugs Revenue Growth Rate Forecast (2022-2027)

North America Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

East Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Europe Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

South Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Middle East Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Africa Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Oceania Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

South America Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Rest of the world Duchenne Muscular Dystrophy Drugs Consumption Forecast 2022-2027

Bottom-up and Top-down Approaches for This Report

## I would like to order

Product name: Global Duchenne Muscular Dystrophy Drugs Market Research Report 2022 Professional Edition

Product link: <https://marketpublishers.com/r/GF49F223108BEN.html>

Price: US\$ 2,890.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF49F223108BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

